Clinical Trials
Bristol-Myers Squibb announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes
Bristol-Myers Squibb Company and AstraZeneca announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on metformin therapy alone. The study demonstrated dapagliflozin was non-inferior compared to glipizide (sulphonylurea) in improving...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read